MTOR and polycystic ovary syndrome: In mammalian models, miR-28-5p has reportedly reduced PCOS pathogenesis by targeting the 3′-UTR of PROK1, which has involvement in the PI3K/AKT/mTOR signaling pathways, indicating the miR-28-5p/PROK1 axis as a potential target in PCOS treatment [177].